Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Rein Therapeutics (RNTX) Accumulated Depreciation & Amortization (2016 - 2023)

Rein Therapeutics (RNTX) has disclosed Accumulated Depreciation & Amortization for 8 consecutive years, with $358000.0 as the latest value for Q4 2023.

  • Quarterly Accumulated Depreciation & Amortization rose 32.59% to $358000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $358000.0 through Dec 2023, up 32.59% year-over-year, with the annual reading at $358000.0 for FY2023, 32.59% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2023 was $358000.0 at Rein Therapeutics, up from $295000.0 in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $629000.0 in Q3 2020, with the low at $166000.0 in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $319764.7, with a median of $270000.0 recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization crashed 70.42% in 2021, then skyrocketed 35.12% in 2022.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $522000.0 in 2019, then plummeted by 68.2% to $166000.0 in 2020, then increased by 27.71% to $212000.0 in 2021, then increased by 27.36% to $270000.0 in 2022, then surged by 32.59% to $358000.0 in 2023.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $358000.0, $295000.0, and $285000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.